Siemens Healthineers Forecast, price target & analysts
Siemens Healthineers Target price 2025 - Analyst rating & recommendation
Siemens Healthineers Classifications & Recommendation:
Siemens Healthineers Price Target
| Target Price | €63.07 |
| Price | €46.52 |
| Potential | 35.58% |
| Number of Estimates | 20 |
| 20 Analysts have issued a price target Siemens Healthineers 2026 . The average Siemens Healthineers target price is €63.07. This is 35.58% higher than the current stock price. The highest price target is €75.00 61.22% , the lowest is €53.00 13.93% . | |
| A rating was issued by 21 analysts: 17 Analysts recommend Siemens Healthineers to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Siemens Healthineers stock has an average upside potential 2026 of 35.58% . Most analysts recommend the Siemens Healthineers stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2029
19 Analysts have issued a sales forecast Siemens Healthineers 2025 . The average Siemens Healthineers sales estimate is €23.8b . This is 5.10% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €24.3b 7.36% , the lowest is €23.4b 3.18% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | €22.4b | 3.15% |
|---|---|---|
| 2025 | €23.8b | 6.54% |
| 2026 | €25.4b | 6.45% |
| 2027 | €26.9b | 6.24% |
| 2028 | €28.5b | 5.82% |
| 2029 | €30.4b | 6.49% |
18 Analysts have issued an Siemens Healthineers EBITDA forecast 2025. The average Siemens Healthineers EBITDA estimate is €5.0b . This is 6.02% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €5.4b 14.13% , the lowest is €4.6b 1.62% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | €4.5b | 13.16% |
|---|---|---|
| 2025 | €5.0b | 10.29% |
| 2026 | €5.6b | 11.52% |
| 2027 | €6.1b | 10.01% |
| 2028 | €6.6b | 7.93% |
| 2029 | €7.2b | 8.69% |
EBITDA Margin
| 2024 | 20.23% | 9.70% |
|---|---|---|
| 2025 | 20.94% | 3.53% |
| 2026 | 21.93% | 4.73% |
| 2027 | 22.71% | 3.56% |
| 2028 | 23.16% | 1.98% |
| 2029 | 23.64% | 2.07% |
12 Siemens Healthineers Analysts have issued a net profit forecast 2025. The average Siemens Healthineers net profit estimate is €2.4b . This is 18.94% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €2.5b 25.56% , the lowest is €2.2b 12.60% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | €1.9b | 28.89% |
|---|---|---|
| 2025 | €2.4b | 20.99% |
| 2026 | €2.9b | 21.28% |
| 2027 | €3.2b | 12.47% |
| 2028 | €3.5b | 10.16% |
| 2029 | €3.9b | 11.44% |
Net Margin
| 2024 | 8.71% | 24.95% |
|---|---|---|
| 2025 | 9.89% | 13.56% |
| 2026 | 11.27% | 13.95% |
| 2027 | 11.93% | 5.86% |
| 2028 | 12.42% | 4.11% |
| 2029 | 12.99% | 4.59% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
12 Analysts have issued a Siemens Healthineers forecast for earnings per share. The average Siemens Healthineers EPS is €2.11 . This is 19.21% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.22 25.42% , the lowest is €1.99 12.43% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | €1.74 | 28.89% |
|---|---|---|
| 2025 | €2.11 | 21.26% |
| 2026 | €2.55 | 20.85% |
| 2027 | €2.87 | 12.55% |
| 2028 | €3.16 | 10.10% |
| 2029 | €3.53 | 11.71% |
P/E ratio
| Current | 26.79 | 35.88% |
|---|---|---|
| 2025 | 22.10 | 17.51% |
| 2026 | 18.22 | 17.56% |
| 2027 | 16.20 | 11.09% |
| 2028 | 14.70 | 9.26% |
| 2029 | 13.20 | 10.20% |
Based on analysts' sales estimates for 2025, the Siemens Healthineers stock is valued at an EV/Sales of 2.77 and an P/S ratio of 2.19 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 2.91 | 18.72% |
|---|---|---|
| 2025 | 2.77 | 4.85% |
| 2026 | 2.60 | 6.06% |
| 2027 | 2.45 | 5.87% |
| 2028 | 2.31 | 5.50% |
| 2029 | 2.17 | 6.09% |
P/S ratio
| Current | 2.30 | 20.96% |
|---|---|---|
| 2025 | 2.19 | 4.85% |
| 2026 | 2.05 | 6.06% |
| 2027 | 1.93 | 5.87% |
| 2028 | 1.83 | 5.50% |
| 2029 | 1.71 | 6.10% |
Siemens Healthineers...
Current Siemens Healthineers Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Buy
➜
Buy
|
Unchanged | Jan 02 2025 |
| EQUITA SIM |
Buy
➜
Buy
|
Unchanged | Dec 22 2024 |
| STIFEL EUROPE |
Buy
➜
Buy
|
Unchanged | Dec 17 2024 |
| METZLER EQUITIES |
Buy
➜
Buy
|
Unchanged | Nov 28 2024 |
| HSBC |
Buy
➜
Buy
|
Unchanged | Nov 24 2024 |
| BNP PARIBAS EXANE |
Outperform
➜
Outperform
|
Unchanged | Nov 18 2024 |
| DAY BY DAY |
Buy
➜
Sell
|
Downgrade | Nov 17 2024 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Jan 02 2025 |
|
Unchanged
EQUITA SIM:
Buy
➜
Buy
|
Dec 22 2024 |
|
Unchanged
STIFEL EUROPE:
Buy
➜
Buy
|
Dec 17 2024 |
|
Unchanged
METZLER EQUITIES:
Buy
➜
Buy
|
Nov 28 2024 |
|
Unchanged
HSBC:
Buy
➜
Buy
|
Nov 24 2024 |
|
Unchanged
BNP PARIBAS EXANE:
Outperform
➜
Outperform
|
Nov 18 2024 |
|
Downgrade
DAY BY DAY:
Buy
➜
Sell
|
Nov 17 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
